See more : Brompton Split Banc Corp. (SBC.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Amryt Pharma plc (AMYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amryt Pharma plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sharda Motor Industries Limited (SHARDA.BO) Income Statement Analysis – Financial Results
- Brookfield Wealth Solutions Ltd. (BNT) Income Statement Analysis – Financial Results
- China Starch Holdings Limited (3838.HK) Income Statement Analysis – Financial Results
- Peninsula Group Ltd (PEN.TA) Income Statement Analysis – Financial Results
- MEC Company Ltd. (4971.T) Income Statement Analysis – Financial Results
Amryt Pharma plc (AMYT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.amrytpharma.com
About Amryt Pharma plc
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 222.54M | 182.61M | 58.12M | 16.53M | 15.33M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 106.12M | 119.03M | 42.00M | 6.06M | 6.45M | 616.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 116.42M | 63.58M | 16.12M | 10.47M | 8.88M | 804.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.32% | 34.82% | 27.74% | 63.35% | 57.95% | 56.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.73M | 27.62M | 15.83M | 10.35M | 12.67M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.34M | 4.73M | 841.00K | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Selling & Marketing | 92.00M | 76.67M | 35.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.34M | 81.40M | 36.34M | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.83K | -47.51K | 5.03K | 11.50K |
| Operating Expenses | 138.07M | 109.02M | 52.17M | 27.92M | 25.93M | 6.95M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Cost & Expenses | 244.18M | 228.05M | 94.17M | 33.98M | 32.37M | 7.57M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Interest Income | 5.00K | 87.00K | 92.00K | 5.72K | 6.00K | 1.05K | 185.00K | 201.00K | 319.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.91M | 19.57M | 8.48M | 1.78M | 989.75K | 127.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74M | 44.47M | 12.63M | 354.61K | 310.72K | 204.03K | 6.00K | 6.00K | 4.56K | 0.00 | 99.63K | 147.69K | 144.69K | 224.23K | 161.09K |
| EBITDA | 29.10M | -977.00K | -23.42M | -17.09M | -16.73M | -5.94M | 33.26M | -3.10M | -1.27M | -275.37K | -281.22K | -281.82K | -1.60M | -2.83M | -2.17M |
| EBITDA Ratio | 13.08% | -0.54% | -40.29% | -103.36% | -109.16% | -418.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.64M | -45.44M | -36.04M | -17.44M | -17.04M | -8.08M | -39.93M | -2.93M | -3.51M | -275.37K | -281.22K | -281.82K | -459.87K | -3.28M | -2.43M |
| Operating Income Ratio | -9.72% | -24.89% | -62.01% | -105.51% | -111.18% | -568.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.17M | -60.42M | -30.72M | -12.00M | -14.31M | -127.26K | 189.00K | -36.81M | 376.00K | -1.84M | -5.85K | 0.00 | -63.03K | 7.94K | 14.28K |
| Income Before Tax | -29.81M | -105.86M | -66.76M | -29.45M | -31.36M | -8.21M | -39.74M | -2.56M | -2.12M | -275.37K | -281.22K | -281.82K | -522.90K | -3.27M | -2.41M |
| Income Before Tax Ratio | -13.40% | -57.97% | -114.86% | -178.09% | -204.54% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -11.64M | -1.33M | -1.23M | 41.18K | 14.31M | 1.93M | 73.18M | -175.00K | 2.23M | 550.74K | 2.68M | 1.51K | -25.79K | 226.22K | 101.27K |
| Net Income | -18.17M | -104.53M | -65.54M | -29.49M | -45.67M | -8.21M | -39.74M | -2.56M | -2.12M | -826.12K | -3.06M | -123.58K | -497.11K | -3.27M | -2.41M |
| Net Income Ratio | -8.17% | -57.24% | -112.75% | -178.34% | -297.89% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| EPS Diluted | -0.37 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| Weighted Avg Shares Out | 47.17M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
| Weighted Avg Shares Out (Dil) | 49.40M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
Amryt Granted Orphan Drug Designation by the FDA for AP103
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
Holding(s) in Company
Holding(s) in Company
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
Amryt Announces $40m Private Placement with Leading Biotech Investors
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
Source: https://incomestatements.info
Category: Stock Reports